Cardiomyocyte proliferation in zebrafish and mammals: lessons for human disease.
Cardiomyocytes proliferate profusely during early development and for a brief period after birth in mammals. Within a month after birth, this proliferative capability is dramatically reduced in mammals unlike lower vertebrates where it persists into adult life. The zebrafish, for example, retains the ability to regenerate the apex of the heart following resection by a mechanism predominantly driven by cardiomyocyte proliferation. Differences in proliferative capacity of cardiomyocytes in adulthood between mammals and lower vertebrates are closely liked to ontogenetic or phylogenetic factors. Elucidation of these factors has the potential to provide enormous benefits if they lead to the development of therapeutic strategies that facilitate cardiomyocyte proliferation. In this review, we highlight the differences between Mammalian and Zebrafish cardiomyocytes, which could explain at least in part the different proliferative capacities in these two species. We discuss the advantages of the zebrafish as a model of cardiomyocyte proliferation, particularly at the embryonic stage. We also identify a number of key molecular pathways with potential to reveal key steps in switching cardiomyocytes from a quiescent to a proliferative phenotype.
The University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, EH16 4TJ, Scotland.|Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, 77030, TX, USA.
Gianfranco
G
Matrone
The University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, EH16 4TJ, Scotland.
Carl S
CS
Tucker
The University of Edinburgh/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, EH16 4TJ, Scotland. mdenvir@staffmail.ed.ac.uk.
Martin A
MA
Denvir
D000818:Animals; D006332:Cardiomegaly / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D049109:Cell Proliferation / Q000187:drug effects; D055808:Drug Discovery; D006321:Heart / Q000187:drug effects / Q000196:embryology / Q000254:growth & development; D006335:Heart Injuries / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D006965:Hyperplasia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D032383:Myocytes, Cardiac / Q000166:cytology* / Q000378:metabolism / Q000473:pathology*; D015398:Signal Transduction; D015027:Zebrafish / Q000196:embryology / Q000502:physiology
Heart; Mammals; Proliferation; Regeneration; Zebrafish